Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints

On recurrent-event win ratio

(2022) Lu Mao et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Estimation and modeling of the restricted mean time lost in the presence of competing risks

(2021) Sarah C. Conner et al.   STATISTICS IN MEDICINE

Statistical models for composite endpoints of death and non-fatal events: a review

(2021) Lu Mao et al.   Statistics in Biopharmaceutical Research

Sample size formula for general win ratio analysis

(2021) Lu Mao et al.   BIOMETRICS

On restricted mean time in favor of treatment

(2021) Lu Mao   BIOMETRICS

Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations

(2020) Anne Eaton et al.   Clinical Trials

Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials

(2020) Ying Lu et al.   Statistics in Biopharmaceutical Research

Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease

(2020) Orly Vardeny et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Design and monitoring of survival trials based on restricted mean survival times

(2019) Xiaodong Luo et al.   Clinical Trials

Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies

(2019) Zachary R. McCaw et al.   CIRCULATION

The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards

(2019) Gaohong Dong et al.   PHARMACEUTICAL STATISTICS

Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards

(2019) Godwin Yung et al.   BIOMETRICS

On the alternative hypotheses for the win ratio

(2018) Lu Mao   BIOMETRICS

Estimands and Their Role in Clinical Trials

(2017) Mouna Akacha et al.   Statistics in Biopharmaceutical Research

On the win-ratio statistic in clinical trials with multiple types of event

(2016) D. Oakes   BIOMETRIKA

Estimands in clinical trials - broadening the perspective

(2016) Mouna Akacha et al.   STATISTICS IN MEDICINE

Large sample inference for a win ratio analysis of a composite outcome based on prioritized components: Table 1.

(2015) Ionut Bebu et al.   BIOSTATISTICS

An alternative approach to confidence interval estimation for the win ratio statistic

(2014) Xiaodong Luo et al.   BIOMETRICS

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

(2014) Jennifer K. Rogers et al.   EUROPEAN JOURNAL OF HEART FAILURE

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?

(2012) S. D. Anker et al.   EUROPEAN HEART JOURNAL

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

(2011) S. J. Pocock et al.   EUROPEAN HEART JOURNAL

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE